Sign in
Stories
Adial Pharmaceuticals Raises Capital for AD04 Development
Share
ADMA Biologics CFO Transition Announceme...
ADMA Biologics CFO Transition Revealed
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Innovative REGN4461 for Lipodystrophy Ma...
Overview
API
Adial Pharmaceuticals exercised warrants for stock purchase, raising $3,530,500 for corporate purposes and AD04 drug development.
Ask a question
How might the successful funding round influence investor confidence in Adial Pharmaceuticals?
How will the capital infusion impact Adial Pharmaceuticals' research and development pipeline?
What potential benefits can AD04 bring to individuals suffering from Alcohol Use Disorder?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage